Peter Kiener, Ph.D.

Dr. Kiener is an industry veteran with extensive experience in oncology,  biologics and immunotherapy, and across the entire value chain of biopharmaceutical research and development.

Peter was the former Chief Scientific Officer at Sucampo Pharmaceuticals, Inc., until the company’s acquisition by Mallinckrodt PLC in February 2018. Prior to joining Sucampo, he served as CSO of Ambrx, Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates.

Prior to Ambrx, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. Peter held several executive leadership roles including as the Executive Vice President and Global Head of Biologics Research and Development at MedImmune LLC, which became the global biologics arm of AstraZeneca. 

Peter has led or contributed to the development and regulatory approval of multiple drugs including antibodies, fusion proteins, and vaccines. Dr. Kiener is a member of the Board of Directors of Cue Biopharma, Wugen, Pieris, and iTolerance and is a consultant/advisor to biotech companies and to ICG Life Sciences, a UK venture fund. 

Dr. Kiener earned a bachelor’s degree in chemistry from the Lancaster University and a doctorate of philosophy in biochemistry from the University of Oxford. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications.